Population-Based Resequencing of APOA1 in 10,330 Individuals: Spectrum of Genetic Variation, Phenotype, and Comparison with Extreme Phenotype Approach

PLoS Genetics

Volumn 8, Issue 11, 2012, Pages

  Haase, Christiane L ^a,b   Frikke Schmidt, Ruth ^a,b,c   Nordestgaard, Børge G ^b,c,d   Tybjærg Hansen, Anne ^a,b,c,d  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AMYLOIDOSIS; APOLIPOPROTEIN A1 GENE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTER MODEL; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTREME PHENOTYPE APPROACH; FEMALE; GENE; GENE DISTRIBUTION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CONSERVATION; GENETIC PARAMETERS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONSYNONYMOUS VARIANT; NUCLEOTIDE SEQUENCE; PHENOTYPE; POPULATION BASED RESEQUENCING; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYNONYMOUS VARIANT; VALIDATION PROCESS;

AMYLOIDOSIS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84870705395     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003063     Document Type: Article

References (42)

1. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. (2009) Finding the missing heritability of complex diseases. Nature 461: 747-753.
2. Cirulli ET, Goldstein DB, (2010) Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 11: 415-425.
3. Tall AR, Breslow JL, Rubin EM (2001) Genetic disorders affecting plasma high-density lipoproteins. In: Schriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited diseases. New York, NY: McGraw-Hill. pp. 2915-2936.
4. Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F, (2009) Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: A systematic in-depth review. Exp Gerontol 44: 136-160.
5. Sorci-Thomas MG, Thomas MJ, (2002) The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 12: 121-128.
6. Zannis VI, Chroni A, Krieger M, (2006) Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 84: 276-294.
7. Benson MD, (2005) Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 12: 75-87.
8. Obici L, Palladini G, Giorgetti S, Bellotti V, Gregorini G, et al. (2004) Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 126: 1416-1422.
9. de Sousa MM, Vital C, Ostler D, Fernandes R, Pouget-Abadie J, et al. (2000) Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 156: 1911-1917.
10. Persey MR, Booth DR, Booth SE, Zyl-Smit R, Adams BK, et al. (1998) Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int 53: 276-281.
11. Rall SC Jr, Weisgraber KH, Mahley RW, Ogawa Y, Fielding CJ, et al. (1984) Abnormal lecithin:cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted. J Biol Chem 259: 10063-10070.
12. Haase CL, Tybjærg-Hansen A, Grande P, Frikke-Schmidt R, (2010) Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 95: E500-E510.
13. Haase CL, Frikke-Schmidt R, Nordestgaard BG, Kateifides AK, Kardassis D, et al. (2011) Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. J Int Med 270: 136-146.
14. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjærg-Hansen A, (2004) Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 114: 1343-1353.
15. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, et al. (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305: 869-872.
16. Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, et al. (2006) Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA 103: 1810-1815.
17. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG, (2002) Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12000 men and women from The Copenhagen City Heart Study. Eur Heart J 23: 620-626.
18. Frikke-Schmidt R, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, et al. (2008) Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299: 2524-2532.
19. Zacho J, Tybjærg-Hansen A, Jensen JS, Grande P, Sillesen H, et al. (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897-1908.
20. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, et al. (2007) Universal definition of myocardial infarction. Eur Heart J 28: 2525-2538.
21. The Joint European Society of Cardiology/American College of Cardiology Committee (2000) Myocardial infarction redefined- A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 21: 1502-1513.
22. Friedewald WT, Levy RI, Friedrickson DS, (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
23. Tybjærg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG, (1998) Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 338: 1577-1584.
24. Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, et al. (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 179: 1978-1987.
25. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjærg-Hansen A, et al. (2007) Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 39: 513-516.
26. Coventry A, Bull-Otterson LM, Liu X, Clark AG, Maxwell TJ, et al. (2010) Deep resequencing reveals excess rare recent variants consistent with explosive population growth. Nat Commun 1: 131.
27. Araki K, Sasaki J, Matsunaga A, Takada Y, Moriyama K, et al. (1994) Characterization of two new human apolipoprotein A-I variants: apolipoprotein A-I Tsushima (Trp-108→Arg) and A-I Hita (Ala-95→Asp). Biochim Biophys Acta 1214: 272-278.
28. von Eckardstein A, Funke H, Walter M, Altland K, Benninghoven A, et al. (1990) Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. J Biol Chem 265: 8610-8617.
29. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707-713.
30. Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, et al. (2008) Discrete roles of apoA-I and apoE in the biogenesis of HDL species: Lessons learned from gene transfer studies in different mouse models. Ann Med 40 Suppl 1: 14-28.
31. Menzel HJ, Assmann G, Rall SC Jr, Weisgraber KH, Mahley RW, (1984) Human apolipoprotein A-I polymorphism. Identification of amino acid substitutions in three electrophoretic variants of the Münster-3 type. J Biol Chem 259: 3070-3076.
32. von Eckardstein A, Funke H, Henke A, Altland K, Benninghoven A, et al. (1989) Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I. J Clin Invest 84: 1722-1730.
33. Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, et al. (1996) Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation 94: 1622-1628.
34. Kiss RS, Kavaslar N, Okuhira Ki, Freeman MW, Walter S, et al. (2007) Genetic etiology of isolated low HDL syndrome: Incidence and heterogeneity of efflux defects. Arterioscler Thromb Vasc Biol 27: 1139-1145.
35. Matsunaga T, Hiasa Y, Yanagi H, Maeda T, Hattori N, et al. (1991) Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci USA 88: 2793-2797.
36. Fullerton M, Buchanan V, Sonpar A, Taylor L, Smith D, et al. (2004) The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster. Hum Genet V115: 36-56.
37. Utermann G, Feussner G, Franceschini G, Haas J, Steinmetz A, (1982) Genetic variants of group A apolipoproteins. Rapid methods for screening and characterization without ultracentrifugation. J Biol Chem 257: 501-507.
38. Amarzguioui M, Mucchiano G, Häggqvist B, Westermark P, Kavlie A, et al. (1998) Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem Biophys Res Commun 242: 534-539.
39. Tilly-Kiesi M, Packard CJ, Kahri J, Ehnholm C, Shepherd J, et al. (1997) In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107→0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency. Atherosclerosis 128: 213-222.
40. Tilly-Kiesi M, Qiuping Z, Ehnholm S, Kahri J, Lahdenpera S, et al. (1995) ApoA-IHelsinki (Lys107→0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency. Arterioscler Thromb Vasc Biol 15: 1294-1306.
41. Recalde D, Velez-Carrasco W, Civeira F, Cenarro A, Gomez-Coronado D, et al. (2001) Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apoA-IZaragoza (L144R). Atherosclerosis 154: 613-623.
42. Falk RH, Dubrey SW, (2010) Amyloid heart disease. Prog Cardiovasc Dis 52: 347-361.